Overview

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Status:
Completed

Trial end date:
2018-07-31

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.

Phase:

Phase 3

Details

Lead Sponsor:

Foamix Ltd.
Vyne Therapeutics Inc.

Collaborator:

Premier Research Group plc

Treatments:

Minocycline